Table 1.
Patient and treatments characteristics
| Number of patients (%) | ||||
|---|---|---|---|---|
| Cyberknife® n = 38 | CBCT n = 68 | Total n = 106 | p-value | |
| Age, years | ||||
| Mean ± SD | 74.2 (8.7) | 72.7 (8.1) | 73.2 (8.3) | 0.3433 |
| Median (min-max) | 74.9 (55.7–90.5) | 73.4 (54.5–84.1) | 74.8 (54.5–90.5) | |
| Sex | ||||
| Male | 34 (89.5%) | 55 (80.9%) | 89 (83.9%) | 0.2477 |
| Histology | ||||
| Not histologically proven | 11 (28.9%) | 27 (39.7%) | 38 (35.8%) | 0.2243 |
| Adenocarcinoma | 12 (31.6%) | 20 (29.4%) | 32 (30.2%) | |
| Epidermoïd carcinoma | 15 (39.5%) | 16 (23.5%) | 31 (29.2%) | |
| Other | 0 (0%) | 4.(5.9%) | 4 (3.8%) | |
| Tumor stagea | 0.2243 | |||
| Stage IA | 25 (65.8%) | 50 (74.6%) | 75 (71.4%) | |
| Stage IB | 13 (34.2%) | 16 (23.9%) | 29 (27.6%) | |
| Stage IIA | 0 (0%) | 1 (1.5%) | 1 (0.9%) | |
| History of thoracic surgery | 6 (15.8%) | 18 (26.5%) | 24 (22.6%) | 0.5293 |
| Cardiovascular disease | 26 (68.4%) | 42 (61.8%) | 68 (64.1%) | 0.4931 |
| Past-pulmonary disease | 33 (86.8%) | 57 (83.8%) | 90 (84.9%) | 0.6772 |
| Other comorbidities | 27 (71.1%) | 48 (70.6%) | 75 (70.7%) | 0.9598 |
| Corticotherapy during RT | 9 (23.7%) | 21 (30.9%) | 30 (28.3%) | 0.4301 |
| GTV in cm3 | ||||
| Median (min-max) | 10.5 (2.0–129.0) | 9.0 (0.0–89.0) | 9.0 (0.0–129.0) | 0.2486 |
| PTV in cm3 | ||||
| Median (min-max) | 34.00 (2.00–337.0) | 32.50 (5.00–130.0) | 33.5 (2.0–337.0) | 0.9869 |
| Number of fractions | ||||
| Median (min-max) | 3.0 (3.0–5.0) | 4.0 (3.0–9.0) | 4.0 (3.0–9.0) | <0.0001 |
| Total radiation dose on PTV in Gy Median (min-max) |
60 (37–60) | 48 (36–60) | 48 (36–60) | <0.0001 |
ECOG, Eastern Cooperative Oncology Group; GTV, Gross Tumor Volume; PTV, Planning Target Volume.
(a) 14 missing data.
a
according to 6th TNM IASLC stage classification.